<< $1.3 billion in Detroit hospital upgrades could drive up health costs | At least 3.5M Pakistanis have no access to clean water, raising risk for waterborne diseases >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Nederlands | हिन्दी | Русский | Polski

ThermoGenesis files Certificate of Amendment for reverse stock split

Published on August 27, 2010 at 2:51 AM · No Comments

ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said it has filed a Certificate of Amendment to its Amended and Restated Certification of Incorporation to effect its previously announced one-for-four reverse stock split of its common stock.

The split-adjusted shares of the Company's common stock will begin trading on the NASDAQ tomorrow. The Company's shares will continue to trade under the symbol "KOOL," with a "D" added for 20 trading days to signify the reverse stock split has occurred. A new CUSIP number has been assigned to the Company's common stock as a result of the reverse stock split.

The one-for-four reverse stock split will convert all shares of the Company's common stock issued and outstanding, plus all outstanding stock options, restricted stock and the number of shares of common stock available for issuance under the Company's approved stock plans.

The reverse split was approved by the Company's stockholders at a special meeting and authorized by its Board of Directors on August 9, 2010. It will reduce the Company's outstanding common stock from approximately 56.1 million shares, as of its most recent quarterly report on Form 10-Q, to approximately 14.0 million shares.

"We appreciate the support of our stockholders in approving this authorization," said J. Melville Engle, Chief Executive officer of ThermoGenesis. "We ended fiscal 2010 in strong fashion and believe the programs we have in place will result in a successful fiscal 2011 and lead to enhanced long term stockholder value as we continue our focus on the development of enabling technologies for the stem cell regenerative medicine market," he added.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading